a group of pills and capsules

This month, the second wave of biosimilar Humira (adalimumab) sponsors ― as many as eight ― become free to launch their products. July also brings an end to Hikma’s six-month monopoly on generic competition to Jazz Pharmaceuticals’ Xyrem (sodium oxybate) 0.5g/ml oral solution in the US. Read on for additional generics highlights.

Related resources

A man holding a test tube
JUN 23, 2023

Generics Bulletin Explains: The Next Wave of US Humira Biosimilars

Generics Bulletin breaks down all the different Humira biosimilars players and how they are positioning themselves in such a competitive US market.

DEC 01, 2022

In Vivo Outlook 2023

Outlook 2023 includes exclusive interviews and features on topics that reach across the life sciences.

Q2 2023 Outlook Report_resource-card-thumbnail
MAR 01, 2023

Q2 2023 Pharma Outlook Report

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q2 2023.